PR(301230.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
PR
301230.SZ
PharmaResources (Shanghai) Co., Ltd. engages in new drug research, development, and commercial production in China. It offers small molecule drug CRO, CDMO, and CMO. The company also involved in drug discovery, research, and development of pharmaceutical processes; and customized and commercial production of APIs, and key intermediates.
543.35 B
301230.SZMarket value -Rank by Market Cap -/-

Financial Score

13/06/2026 Update
B
Life Sciences Tools and ServicesIndustry
Industry Ranking9/27
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.44%C
    • Profit Margin6.67%B
    • Gross Margin31.92%C
  • Growth ScoreB
    • Revenue YoY18.52%B
    • Net Profit YoY81.57%A
    • Total Assets YoY-1.16%D
    • Net Assets YoY-1.56%D
  • Cash ScoreA
    • Cash Flow Margin362.55%A
    • OCF YoY18.52%B
  • Operating ScoreC
    • Turnover0.52C
  • Debt ScoreA
    • Gearing Ratio21.73%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    AI healthcare and AI pharmaceutical concepts are experiencing volatile adjustments, with PR falling over 18%, R&G Pharma down nearly 15%, and IMIC, BOJI CRO, GOODWILL, and Berry Genomics all dropping more than 5%

    Wallstreetcn·
    SZ
    301230
    +6.03%
    SZ
    301333
    +3.07%
    SZ
    000516
    +2.07%
    Wallstreetcn·
    SZ
    301230
    +6.03%
    SZ
    301333
    +3.07%
    SZ
    000516
    +2.07%

    PR: At this stage, the direct revenue from the company's DiOrion platform drug development services accounts for a small proportion of the company's overall operating income, which does not have a significant impact on the company's overall operating situation

    Wallstreetcn·
    SZ
    301230
    +6.03%
    Wallstreetcn·
    SZ
    301230
    +6.03%

    PR released its performance for the first three quarters, with a net profit attributable to the parent company of 34.7496 million yuan, an increase of 127.96%

    Zhitong·
    SZ
    301230
    +6.03%
    Zhitong·
    SZ
    301230
    +6.03%

    PR: It plans to distribute 13.754 million yuan in cash for the first three quarters of 2025

    Zhitong·
    SZ
    301230
    +6.03%
    Zhitong·
    SZ
    301230
    +6.03%

    The innovative drug concept surged in the afternoon, with Nossan hitting the 20% limit up, followed by gains in PR, Tigermed, Jiuzhou Pharma, and Highfine

    Zhitong·
    SZ
    301230
    +6.03%
    SZ
    300347
    +0.30%
    HK
    03347
    +1.12%
    Zhitong·
    SZ
    301230
    +6.03%
    SZ
    300347
    +0.30%
    HK
    03347
    +1.12%
    © 2026 Longbridge｜Disclaimer